Svb Leerink Comments on Health Catalyst’s FY2019 Earnings (NASDAQ:HCAT)

Health Catalyst (NASDAQ:HCAT) – Equities research analysts at Svb Leerink increased their FY2019 earnings per share (EPS) estimates for shares of Health Catalyst in a report issued on Tuesday, November 12th. Svb Leerink analyst D. Grosslight now anticipates that the company will earn ($1.07) per share for the year, up from their previous forecast of ($1.15). Svb Leerink currently has a “Outperform” rating and a $55.00 price target on the stock. Svb Leerink also issued estimates for Health Catalyst’s Q1 2020 earnings at ($0.27) EPS, Q2 2020 earnings at ($0.18) EPS, FY2020 earnings at ($0.86) EPS and FY2022 earnings at ($0.54) EPS.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald started coverage on shares of Health Catalyst in a research report on Tuesday, October 29th. They set an “overweight” rating and a $47.00 target price on the stock. Piper Jaffray Companies started coverage on shares of Health Catalyst in a research report on Monday, August 19th. They set an “overweight” rating and a $47.00 target price on the stock. Leerink Swann started coverage on shares of Health Catalyst in a research report on Monday, August 19th. They set an “outperform” rating and a $55.00 target price on the stock. Zacks Investment Research raised shares of Health Catalyst from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research report on Friday. Finally, Evercore ISI started coverage on shares of Health Catalyst in a research report on Monday, August 19th. They set an “outperform” rating and a $50.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $49.33.

NASDAQ HCAT opened at $34.37 on Friday. The stock’s fifty day moving average price is $30.39. Health Catalyst has a 52 week low of $26.00 and a 52 week high of $49.85.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. The firm had revenue of $39.40 million for the quarter, compared to analyst estimates of $37.77 million. Health Catalyst’s quarterly revenue was up 19.8% compared to the same quarter last year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nepsis Inc. acquired a new stake in Health Catalyst in the third quarter valued at $3,101,000. Conestoga Capital Advisors LLC acquired a new stake in Health Catalyst in the third quarter valued at $3,249,000. Emerald Advisers LLC acquired a new stake in Health Catalyst in the third quarter valued at $631,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Health Catalyst in the third quarter valued at $542,000. Finally, Dean Capital Investments Management LLC acquired a new stake in Health Catalyst in the third quarter valued at $485,000. 0.81% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Read More: Understanding the different types of bonds

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.